This study explored the self-management strategies utilized by female breast cancer patients to cope with the impact of chemotherapy-induced peripheral neuropathy (CIPN) symptoms. We also examined the variety of taxane-related side effects in women with and without CIPN in order to discriminate the CIPN symptom experience.
A purposive sample of 25 patients treated with docetaxel or paclitaxel were recruited, half with and half without CIPN. Semistructured interviews and patient level data were utilized for this exploratory, descriptive study. Interview data were analyzed with the constant comparative method; patient level data were abstracted from the electronic medical record.
Participants were aged 24–60 years, were currently receiving chemotherapy or within 6 months of having completed treatment, and 14 had CIPN. CIPN impacted routine activities, functions, and behaviors in the areas of domestic, work, and social/leisure life. Multiple self-management and coping strategies to minimize the impact of CIPN symptoms were reported; the focus was on movement to reduce symptoms, attitude awareness, logistics to simplify demands, and environmental change. Women with and without CIPN were similar in the quantity and type of other reported side effects.
CIPN affects breast cancer patients’ routine activities, functions, and behaviors, but they develop management strategies to reduce the impact. The management strategies reported in this study suggest breast cancer patients may adopt interventions that focus on exercise, mindfulness, occupational therapy, and environmental planning toward the goal of reducing the impact of CIPN symptoms on their lives.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Cancer trends progress report—2009/2010 update (2010). National Cancer Institute, NIH, DHHS, Bethesda, MD. http://progressreport.cancer.gov. Accessed 3 June 2011
Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB et al (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90:1205–1211
Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352:930–942
Chirivella I, Bermejo B, Insa A, Perez-Fidalgo A, Magro A, Rosello S et al (2009) Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Trial 114:479–484
Chang J (2000) Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 36(Suppl 1):S11–S14
Basch E (2010) The missing voice of patients in drug-safety reporting. N Engl J Med 362:865–869
Wang J, Huang Y (2007) Pharmacogenomics of sex difference in chemotherapeutic toxicity. Curr Drug Discov Technol 4:59–68
Erban JK, Lau J (2006) On the toxicity of chemotherapy for breast cancer—the need for vigilance. J Natl Cancer Inst 98:1096–1097
Hassett MJ, O’Malley AJ, Pakes JR, Newhouse JP, Earle CC (2006) Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98:1108–1117
Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439
Moore S (2007) Managing treatment side effects in advanced breast cancer. Semin Oncol Nurs 23:S23–S30
Nahleh Z, Tabbara IA (2003) Complementary and alternative medicine in breast cancer patients. Palliat Support Care 1:267–273
Speck RM, Courneya KS, Masse LC, Duval S, Schmitz KH (2010) An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv 4:87–100
Cavaletti G, Marmiroli P (2010) Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 6:657–666
Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44:1507–1515
Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C (2007) Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 11:901–913
Bakitas MA (2007) Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res 56:323–331
Boehmke MM, Dickerson SS (2005) Symptom, symptom experiences, and symptom distress encountered by women with breast cancer undergoing current treatment modalities. Cancer Nurs 28:382–389
Tofthagen C (2010) Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 14:E22–E28
In: Bickman L, Rog DJ (eds) Handbook of applied social research methods. Sage Publications, Thousand Oaks, CA, pp 69–100
Patton M (2002) Qualitative research and evaluation methods. Sage Publications, London
Kemper EA, Stringfield S, Teddlie C (2003) Mixed methods sampling strategies in social science research. In: Tashakkori A, Teddlie C (eds) Handbook of mixed methods in social and behavioral research. Sage Publications, Thousand Oaks, CA, pp 273–296
Paice JA (2009) Clinical challenges: chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs 25:S8–S19
Dunlap B, Paice JA (2006) Chemotherapy-induced peripheral neuropathy: a need for standardization in measurement. J Support Oncol 4:398–399
Kuroi K, Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S et al (2008) A questionnaire survey of physicians’ perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer. Jpn J Clin Oncol 38:748–754
National Cancer Institute (2009) Common Terminology Criteria for Adverse Events v4.0. NCI, NIH, DHHS. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 10 August 2011
QSR International (2008) Nvivo qualitative data analysis software version 8 edn. QSR International
Boeije H (2002) A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual Quant 36:391–409
Velos I (2011) Velos eResearch. Velos, Fremont, CA
Sasane M, Tencer T, French A, Maro T, Beusterien KM (2010) Patient-reported outcomes in chemotherapy-induced peripheral neuropathy: a review. J Support Oncol 8:E15–E21
National Cancer Institute Symptom Management and Quality of Life Steering Committee: chemotherapy-induced peripheral neuropathy (2009) National Cancer Institute, Rockville, MD. http://transformingtrials.cancer.gov/files/CIPN_CTPM_Final_Executive_Summary_for_CCCT_Aug_2010.pdf. Accessed 3 June 2011
Rothman M, Burke L, Erickson P, Leidy NK, Patrick DL, Petrie CD (2009) Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR good research practices for evaluating and documenting content validity for the use of existing instruments and their Modification PRO task force report. Value Health 12:1075–1083
Webb TL, Sheeran P (2006) Does changing behavioral intentions engender behavior change? A meta-analysis of the experimental evidence. Psychol Bull 132:249–268
Klesges LM, Estabrooks PA, Dzewaltowski DA, Bull SS, Glasgow RE (2005) Beginning with the application in mind: designing and planning health behavior change interventions to enhance dissemination. Ann Behav Med 29(Suppl):66–75
Conflicts of Interest
About this article
Cite this article
Speck, R.M., DeMichele, A., Farrar, J.T. et al. Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients. Support Care Cancer 20, 2433–2439 (2012). https://doi.org/10.1007/s00520-011-1365-8
- Chemotherapy-induced peripheral neuropathy
- Symptom management
- Coping strategies